Department of Pharmacology and Physiology, George Washington University School of Medicine and Health Sciences, Washington, DC.
Department of Neurology, George Washington University School of Medicine and Health Sciences, Washington, DC.
Ann N Y Acad Sci. 2018 Feb;1413(1):136-142. doi: 10.1111/nyas.13555. Epub 2018 Jan 21.
Because of the failure of many promising therapeutics identified in preclinical evaluation, funding sources have established guidelines for increased rigor in animal evaluations. The myasthenia gravis (MG) community of scientists has developed guidelines for preclinical assessment for potential MG treatments. Here, we provide a focused summary of these recommendations and the role of complement in disease development in experimental models of MG.
由于在临床前评估中确定的许多有前途的治疗方法都失败了，因此资金来源为动物评估增加了严格性的指导方针。重症肌无力（MG）科学家社区已经制定了用于潜在 MG 治疗的临床前评估指南。在这里，我们重点总结了这些建议以及补体在 MG 实验模型中疾病发展中的作用。
